CN101679427B - Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics - Google Patents
Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics Download PDFInfo
- Publication number
- CN101679427B CN101679427B CN200880020027XA CN200880020027A CN101679427B CN 101679427 B CN101679427 B CN 101679427B CN 200880020027X A CN200880020027X A CN 200880020027XA CN 200880020027 A CN200880020027 A CN 200880020027A CN 101679427 B CN101679427 B CN 101679427B
- Authority
- CN
- China
- Prior art keywords
- methyl
- compound
- alkyl
- amino
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
The invention relates to derivatives of 7-alkynyl-1,8-naphthyridones having general formula (I), in which R1, R2, R3 and R4are as defined in the description. The invention also relates to the preparation method thereof and to the use of same in therapeutics.
Description
The present invention relates to 7-alkynyl-1,8-naphthyridinone derivatives, their preparation and their application in therapeutics.
Purpose of the present invention is the compound corresponding to formula (I):
Wherein
R
1
And R
2
(1)Independently of one another expression:
. or hydrogen atom,
. or the C1-C7 alkyl ,-CO-(C1-C7) alkyl or C3-C8 cycloalkyl, wherein said alkyl and cycloalkyl are randomly replaced by one or more groups that are selected from halogen atom and hydroxyl and alkoxyl group,
. or randomly be selected from the phenyl that following group replaces with one or more: halogen atom, C1-C4 alkyl, C1-C4 alkoxyl group, hydroxyl ,-halogenated alkoxy ,-haloalkyl ,-CN or-NRR ', wherein R and R ' are following defines,
. randomly (be included on the nitrogen-atoms of described heteroaryl) in arbitrary position with one or more and be selected from the heteroaryl that following group replaces: halogen atom, C1-C4 alkyl and NRR ' group, wherein R and R ' such as below definition,
(2) or R1 and R2 form with the carbon atom that carries them:
. or the C4-C8 cycloalkyl,
. or the saturated heterocyclic group of 4-8 chain link, it comprises the heteroatoms that is selected from N, O and S atom,
Can condense with phenyl with described heterocyclic group;
R
3
Representative:
. or the C1-C7 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: halogen atom and hydroxyl, alkoxyl group ,-NRR ' ,-haloalkyl and-SO
2-(C1-C4) alkyl, wherein R and R ' be such as hereinafter definition,
. or-(CH
2)
n-heterocyclic group, n=0,1,2 or 3 wherein, wherein this heterocyclic group comprises 4-8 chain link and comprises the heteroatoms that at least one is selected from N, O and S atom, and wherein said heterocyclic group randomly replaces with oxo group,
. or-(CH
2)
n-heteroaryl, n=0,1,2 or 3 wherein, wherein this heteroaryl comprises 5 or 6 chain links and comprises one or more heteroatomss that are selected from nitrogen, oxygen and sulphur.
R4 representsHydrogen atom, C1-C4 alkyl or C1-C4 alkoxyl group,
R and R 'Represent independently of one another hydrogen atom, C1-C4 alkyl.
Formula (I) compound can comprise one or more unsymmetrical carbons.Therefore they can exist with enantiomer, diastereoisomer.These enantiomers, diastereoisomer and their mixture (comprising their racemic mixture at this) form a part of the present invention.
Formula (I) compound can exist with alkali or with the form of acid or alkali (especially pharmaceutically acceptable acid or alkali) salify.This additive salt consists of a part of the present invention.These salt advantageously use pharmaceutically acceptable acid or alkali to be prepared, but the salt of other acid or alkali (acid or the alkali that for example are used for purifying or separate type (I) compound) also consists of a part of the present invention.
Can also be with the form of hydrate or solvate according to compound of the present invention, the form existence of namely being combined with one or more water moleculess or with solvent or associating.This hydrate and solvate also form a part of the present invention.
In the context of the present invention, unless explain in addition in this article, otherwise:
-alkyl: comprise the radical of saturated aliphatic group of 1-7 carbon atom (advantageously 1-4 carbon atom), and it is straight chain, maybe can be for straight chain, side chain or part cyclisation when this alkyl chain comprises at least 3 carbon atoms.As an example, can mention methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, methylene radical-cyclopropyl, methylene radical-cyclohexyl, amyl group, 2,2-dimethyl propyl, hexyl, heptyl etc.;
-cycloalkyl: comprise the cyclic alkyl of 3-8 carbon atom, wherein all carbon atoms all are included in the ring.Can mention cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and suberyl;
-alkoxyl group :-O-alkyl, wherein alkyl by as top the definition;
-halogen atom is interpreted as: fluorine, chlorine, bromine or iodine.
-haloalkyl: the alkyl that its one or more hydrogen atoms have replaced with halogen atom; For instance, can mention-CF3;
-halogenated alkoxy: the alkoxyl group that its one or more hydrogen atoms have replaced with halogen atom; For instance, can mention-OCF3;
-aryl: monocyclic aryl, such as phenyl;
-heteroaryl: comprise 5 or 6 chain links and comprise one or more heteroatomic aryl that are selected from nitrogen, oxygen and sulphur.For example can mention pyridyl, furyl, thienyl, pyrimidyl, pyrazinyl and thiazolyl; With
-heterocyclic radical: comprise 4-8 chain link and comprise one or more heteroatomic cyclic alkyls that are selected from nitrogen, oxygen and sulphur.For example can mention piperidyl, pyrrolidyl, oxetanyl, tetrahydrofuran base, THP trtrahydropyranyl and tetrahydro-thienyl.
In the object of the invention formula (I) compound, can mention such as undefined little compounds:
R1 and R2
(3) independently of one another representative:
. or hydrogen atom,
. or the C1-C7 alkyl ,-CO-(C1-C7) alkyl or C3-C8 cycloalkyl, wherein said alkyl and cycloalkyl randomly replace with one or more groups that are selected from halogen atom and hydroxyl and alkoxyl group,
. or randomly be selected from the phenyl that following group replaces with one or more: halogen atom, C1-C4 alkyl, C1-C4 alkoxyl group, hydroxyl ,-OCF
3,-CF
3,-CN ,-NRR ' group, wherein R and R ' such as below definition,
. or randomly (be included on the nitrogen-atoms of described heteroaryl) in arbitrary position with one or more and be selected from the heteroaryl that following group replaces: halogen atom, C1-C4 alkyl and NRR ' group, wherein R and R ' such as below definition,
(4) or R
1And R
2Form with the carbon atom that carries them:
. or the C4-C8 cycloalkyl,
. or the saturated heterocyclic group of 4-8 chain link, it comprises the heteroatoms that is selected from N, O and S atom,
Can condense with phenyl with described heterocyclic group;
R
3
Representative:
. or the C1-C7 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: halogen atom and hydroxyl, alkoxyl group ,-NRR ', CF
3With-SO
2-(C1-C4) alkyl, wherein R and R ' such as hereinafter definition,
. or-(CH
2)
n-heterocyclic group, wherein n=0,1,2 or 3 and wherein this heterocyclic group comprise 4-8 chain link and comprise the heteroatoms that at least one is selected from N, O and S atom, wherein said heterocyclic group randomly replaces with oxo group,
. or-(CH
2)
n-heteroaryl, wherein n=0,1,2 or 3 and wherein this heteroaryl comprise 5 or 6 chain links and comprise one or more heteroatomss that are selected from nitrogen, oxygen and sulphur;
R 4 RepresentativeHydrogen atom, C1-C4 alkyl or C1-C4 alkoxyl group;
R and R 'Represent independently of one another hydrogen atom or C1-C4 alkyl.
In the object of the invention formula (I) compound, can mention following defined little compounds:
R1 and R2
(1) independently of one another representative:
. or hydrogen atom,
. or the C1-C7 alkyl ,-CO-(C1-C7) alkyl or C3-C8 cycloalkyl, wherein said alkyl randomly replaces with one or more groups that are selected from hydroxyl and alkoxyl group,
. or the phenyl that randomly replaces with one or more C1-C4 alkoxyl groups,
. or heteroaryl,
(2) or R
1And R
2Form with the carbon atom that carries them:
. or the C4-C8 cycloalkyl,
. or the saturated heterocyclic group of 4-8 chain link, it comprises the heteroatoms that is selected from N, O and S atom,
Can condense with phenyl with described heterocyclic group;
And/or
R
3
Representative:
. or the C1-C7 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: hydroxyl, alkoxyl group, NRR ', haloalkyl and SO
2-(C1-C4) alkyl, wherein R and R ' such as hereinafter definition,
. or-(CH
2)
n-heterocyclic group, wherein n=0,1,2 or 3 and wherein this heterocyclic group comprise 4-8 chain link and comprise the heteroatoms that at least one is selected from N and O atom, wherein said heterocyclic group randomly replaces with oxo group,
. or-(CH
2)
n-heteroaryl, wherein n=0 or 1 and wherein this heteroaryl comprise 5 or 6 chain links and comprise one or more nitrogen heteroatoms;
And/or
R 4 RepresentativeC
1-C
4Alkyl or C
1-C
4Alkoxyl group;
And/or
R and R 'Each represents straight or branched C1-C4 alkyl.
In the object of the invention formula (I) compound, can mention such as undefined another little compounds:
R
1
And R
2
(1) independently of one another representative:
. or hydrogen atom,
. or the C1-C7 alkyl ,-CO-(C1-C7) alkyl or C3-C8 cycloalkyl, wherein said alkyl randomly replaces with one or more groups that are selected from hydroxyl and alkoxyl group,
. or the phenyl that randomly replaces with one or more C1-C4 alkoxyl groups,
. or heteroaryl
(2) or R
1And R
2Form with the carbon atom that carries them:
. or the C4-C8 cycloalkyl,
. comprise the saturated heterocyclic group of 4-8 chain link of oxygen heteroatom,
Can condense with phenyl with described heterocyclic group;
And/or
R
3
Representative:
. the perhaps C1-C7 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: hydroxyl, alkoxyl group, NRR ', haloalkyl and SO
2-(C1-C4) alkyl, wherein R and R ' such as hereinafter definition;
. perhaps-(CH
2)
n-heterocyclic group, n=0,1,2 or 3 wherein, wherein this heterocyclic group comprises 4-8 chain link and comprises the heteroatoms that at least one is selected from N and O atom, and wherein said heterocyclic group randomly replaces with oxo group,
. perhaps-(CH
2)
n-heteroaryl, wherein n=0 or 1 and wherein this heteroaryl comprise 5 or 6 chain links and comprise one or more nitrogen heteroatoms;
And/or
R 4 RepresentativeC1-C4 alkyl or C1-C4 alkoxyl group;
And/or
R and R 'Each represents the C1-C4 alkyl of straight or branched.
In the object of the invention formula (I) compound, can mention such as the undefined the 3rd little compounds:
R
1
And R
2
(1) independently of one another representative:
. or hydrogen atom,
. or C1-C7 alkyl or C3-C8 cycloalkyl, wherein said alkyl randomly replaces with one or more groups that are selected from hydroxyl and alkoxyl group,
. or the phenyl that randomly replaces with one or more C1-C4 alkoxyl groups,
. or heteroaryl
(2) or R
1And R
2Form the C4-C8 cycloalkyl with the carbon atom that carries them;
And/or
R
3
Representative:
. or the C1-C7 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: hydroxyl, alkoxyl group, haloalkyl and-SO
2-(C1-C4) alkyl;
. or-(CH
2)
n-heterocyclic group, wherein n=0,1,2 or 3 and wherein this heterocyclic group comprise 4-8 chain link and comprise the heteroatoms that at least one is selected from N, O atom, wherein said heterocyclic group randomly replaces with oxo group,
. or-(CH
2)
n-heteroaryl, wherein n=0 or 1 and wherein this heteroaryl comprise 5 or 6 chain links and comprise one or more nitrogen heteroatoms;
And/or
R 4 RepresentativeThe C1-C4 alkyl;
And/or
R and R 'Each represents straight or branched C1-C4 alkyl.
In the object of the invention formula (I) compound, can mention a little compounds, for them,
R
1
And R
2
(1) independently of one another representative:
. or hydrogen atom,
. or the C1-C7 alkyl ,-CO-(C1-C7) alkyl or C3-C8 cycloalkyl, wherein said alkyl randomly replaces with one or more groups that are selected from hydroxyl and alkoxyl group,
. or the phenyl that randomly replaces with one or more C1-C4 alkoxyl groups,
Or heteroaryl
(2) or R1 and R2 form with the carbon atom that carries them:
. or the C4-C8 cycloalkyl,
. or the saturated heterocyclic group of 4-8 chain link, it comprises the heteroatoms that is selected from N, O and S atom,
Can condense with phenyl with described heterocyclic group;
More particularly, in the object of the invention formula (I) compound, can mention a little compounds, for them,
R 1 And/or R 2 Represent pyridyl, thienyl, thiazolyl or pyrazinyl or imidazolyl.
More particularly, in purpose formula of the present invention (I) compound, can mention a little compounds, for them, R
1And R
2Form heterocyclic group with the carbon atom that carries them, this heterocyclic group is selected from tetrahydrofuran base or THP trtrahydropyranyl, and wherein said heterocyclic group can condense with phenyl.
In the object of the invention formula (I) compound, can mention a little compounds, for them,
R
3
Representative:
. the perhaps C1-C7 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: hydroxyl, alkoxyl group, NRR ', haloalkyl and SO
2-(C1-C4) alkyl, wherein R and R ' be such as hereinafter definition,
. perhaps-(CH
2)
n-heterocyclic group, n=0,1,2 or 3 wherein, wherein this heterocyclic group comprises 4-8 chain link and comprises the heteroatoms that at least one is selected from N and O atom, and wherein said heterocyclic group randomly replaces with oxo group,
. perhaps-(CH
2)
n-heteroaryl, n=0 or 1 wherein, wherein this heteroaryl comprises 5 or 6 chain links and comprises one or more nitrogen heteroatoms.
More particularly, in the object of the invention formula (I) compound, can mention a little compounds, for them,
R 3 RepresentativeIts at least 3 carbon atoms carry out the C3-C7 alkyl of cyclisation, and it is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and methylene radical-cyclopropyl.
More particularly, in the object of the invention formula (I) compound, can mention a little compounds, for them,
R 3 Representative-(CH
2)
n-heterocyclic group, n=0,1,2 or 3 wherein, and wherein this heterocyclic group is selected from THP trtrahydropyranyl, tetrahydrofuran base and pyrrolidyl.
More particularly, in the object of the invention formula (I) compound, can mention a little compounds, for them,
R 3 Representative-(CH
2)
n-heteroaryl, wherein n=1 and wherein heteroaryl represent pyridyl.
In the object of the invention formula (I) compound, can mention a little compounds, for them,
R 4 RepresentativeC1-C4 alkyl or C1-C4 alkoxyl group.
In the object of the invention formula (I) compound, can mention a little compounds, for them,
R and R 'Each represents the C1-C4 alkyl of straight or branched.
In the object of the invention compound, can mention following compound especially:
■ 2-amino-1-ethyl-7-(3-hydroxy-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[(1-hydroxycyclopent base) ethynyl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-(3-hydroxyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-(3-hydroxy-3-methyl penta-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-cyclopentyl-3-hydroxyl third-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-cyclopropyl-3-hydroxyl third-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ 2-amino-1-ethyl-7-[(1-hydroxyl cyclobutyl) ethynyl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3,4-dihydroxyl-3-methyl fourth-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ 2-amino-1-ethyl-7-[3-hydroxyl-4-methoxyl group-3-(methoxymethyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-(cyclopropyl methyl)-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-(3-hydroxyl-3-phenyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[3-hydroxyl-3-(3-thienyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[3-hydroxyl-3-(3-p-methoxy-phenyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[3-hydroxyl-3-(4-p-methoxy-phenyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-1-(3-methoxy-propyl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-cyclopentyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-1-sec.-propyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-1-isobutyl--N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ 2-amino-7-(3-hydroxy-3-methyl fourth-1-alkynes-1-yl)-1-(3-methoxy-propyl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-(3-hydroxyl-4-methoxyl group-3-phenyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-(tetrahydropyran-4-base)-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-cyclohexyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[3-hydroxyl-3-(1,3-thiazoles-2-yl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[3-hydroxyl-3-(methoxymethyl) penta-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-[3-(2-oxo-pyrrolidine-1-yl) propyl group]-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-propyl group-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(2,2,2-trifluoroethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxy-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(tetrahydrofuran (THF)-2-ylmethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(pyridine-2-ylmethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-(3-hydroxyl-3-pyrazine-2-Ji Ding-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-cyclopropyl-3-hydroxyl-4-methoxyl group fourth-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[3-hydroxyl-3-(2-thienyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[3-hydroxyl-3-(2-p-methoxy-phenyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-cyclopentyl-7-(3,4-dihydroxyl-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(4-oxyethyl group-3-hydroxy-3-methyl fourth-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-(trans-the 4-hydroxy-cyclohexyl)-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl isophthalic acid-[3-(methyl sulphonyl) propyl group]-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-(cyclopropyl methyl)-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-1-(cyclopropyl methyl)-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-7-(3,4-dihydroxyl-3-methyl fourth-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-7-(3,4-dihydroxyl-3-methyl fourth-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-ethyl-7-(3-hydroxyl-3-phenyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-1-ethyl-7-(3-hydroxyl-3-phenyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-1-(3-methoxy-propyl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-1-(3-methoxy-propyl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-cyclopentyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-1-cyclopentyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-1-sec.-propyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-1-sec.-propyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-cyclohexyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-1-cyclohexyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-ethyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-1-ethyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-propyl group-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-propyl group-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(2,2,2-trifluoroethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(2,2,2-trifluoroethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-1-ethyl-7-[3-hydroxyl-3-(methoxymethyl) penta-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-ethyl-7-[3-hydroxyl-3-(methoxymethyl) penta-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-1-ethyl-7-[3-hydroxyl-3-(3-thienyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-ethyl-7-[3-hydroxyl-3-(3-thienyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide.
According to the present invention, formula (I) compound can be prepared according to the method for expression in scheme 1.
Fig. 1
According to Fig. 1,2 of the formula (II) that can commercial obtain or be prepared according to method known to those skilled in the art, (wherein the X group represents halogen atom to 6-dihalo nicotinic acid, chlorine or bromine preferably) under 20 ℃-150 ℃ temperature, in protonic solvent (such as alcohol or water), use formula R at 2
3-NH
2Amine carry out monosubstitution (R wherein
3Define about the object of the invention formula (I) compound such as the front), this replacement is randomly carried out in the sealing test tube.The 2-amino-nicotinic acid derivatives of acquisition formula (III); in the presence of alkali (such as triethylamine or pyridine) and in inert solvent (such as methylene dichloride); make at ambient temperature this derivative under the effect of cyanuric fluoride, be converted into formula (IV) acid fluoride; as by G.Olah etc. in Synthesis (1973); described in 487; or with other method known to those skilled in the art (as by Mukaiyama and Tanaka in Chem.Lett. (1976); 303; or by Ishikawa and Sasaki in Chem.Lett. (1976), those that describe in 1407) carry out.Make subsequently high reactivity but stable formula (IV) acid fluoride in the presence of highly basic (such as sodium hydride), in polar aprotic solvent (such as dimethyl formamide), the malonamide nitrile reaction that replaces with the N-of formula (V).
If use two kinds of Equivalents of sodium hydride, after spending the night at ambient temperature, acquisition formula (VI) β-c é to-malonamide nitrile, it is subsequently by being heated to 90-125 ℃ temperature (method A) or carrying out also [2,3-b] pyridine alkane ketone of cyclisation acquisition formula (VII) amino-pyridine by processing (method B) with highly basic (such as potassium tert.-butoxide) at ambient temperature in aprotic solvent (preferably tetrahydrofuran (THF)) in polar solvent (such as propyl carbinol, dimethyl sulfoxide (DMSO) or dimethyl formamide).
When two kinds of Equivalents that in the condensation step of derivative (IV) and derivative (V), use sodium hydride, when then stirring at ambient temperature the third Equivalent of introducing NaH after 10-16 hour, the deprotonation compound (VI) that forms carries out cyclisation in position with direct acquisition formula (VII) amino-pyridine also [2 under uniform temp, 3-b] pyridone, have good yield (method C).
In the presence of alkali (such as triethylamine), be less than or equal under 0 ℃ the temperature, the N-alkyl cyanide yl acetamide of formula (V) is by making cyanoacetic acid and alkyl chloroformate (such as isobutyl chlorocarbonate or Vinyl chloroformate) reaction be prepared the intermediate mixed anhydride that then forms and excessive formula R
4-NH
2Amine reaction (R wherein
4Such as the front about being defined by the object of the invention formula (I) compound).
In order to obtain pyrido [2,3-b] the pyridine alkane ketone for the object of the invention formula (I), make formula (VII) halogenation intermediate according to the propargyl alcohol R of method known to those skilled in the art and formula (VIII)
1R
2The suitable derivative coupling of CH (OH) CCH, wherein R
1, R
2As defining for formula (I) compound.For example, at PdCl
2(PPh
3)
2, cuprous iodide, triethylamine and dimethyl formamide exist down, under 80 ℃-120 ℃ temperature, makes intermediate (VII) and suitable formula (VIII) alkynes carry out the Sonogashira coupled reaction.This reaction can and be carried out under microwave radiation in the sealing test tube.
In case of necessity, during the reactions steps of expression in flow process 1, carboxyl or the active function groups that some is positioned on R1, R2 and the R3 group can carry out temporary protection with protecting group known to those skilled in the art, described protecting group is as being described in " Protective Groups in OrganicSynthesis ", Green etc., the 2nd edition (John Wiley ﹠amp; Sons Inc., New York).
In Fig. 1, initial compounds and described reagent when their preparation method is not described, can commercially obtains or describe in the literature or can be prepared according to the method or the method known to those skilled in the art that are described in wherein.
According to a further aspect of the invention, the object of the invention also is formula (VII) compound that defines in Fig. 1.These compounds are as the intermediate in synthesis type (I) compound.
Following examples for example understand the preparation of compounds more according to the invention.These embodiment are not restrictive and only are used for illustrating the present invention.The numbering of illustrative compound is corresponding to the numbering that provides in following table, and this table for example understands chemical structure and the physical properties according to compounds more of the present invention.
Use following abbreviation and empirical formula:
The CuI cuprous iodide
CH
2Cl
2Methylene dichloride
The CLHP high performance liquid chromatography
The CL/SM liquid chromatography/mass spectrometry
The DMF dimethyl formamide
The DMSO dimethyl sulfoxide (DMSO)
Et
3The N triethylamine
H hour
HCl hydrochloric acid
The MHz megahertz
MeOH methyl alcohol
MgSO
4Sal epsom
NaCl sodium-chlor
NH
4Cl ammonium chloride
NH
4OH ammonium hydroxide
NaHCO
3Sodium bicarbonate
Na
2SO
4Sodium sulfate
Ppm 1,000,000/
The THF tetrahydrofuran (THF)
Embodiment 1:2-amino-1-ethyl-7-(3-hydroxy-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (compound N is o.2)
(1.12-amino-ethyl)-6-chlorine apellagrin
Stir 18.0g (84.4 mmole) 2, the solution of 6-dichloro-nicotinic acid in 70% ethylamine solution of 180ml in water 72 hours in envrionment temperature.Then then the vapourisation under reduced pressure excess amine adds 10% acetic acid aqueous solution until the product precipitation.Make the beige solid dehydration, with cold water flush and dry in baking oven.Obtain 10.5g expectation product.Fusing point: 158-160 ℃.Yield=62%.
(1.2:2-amino-ethyl)-6-chloronicotinoyl fluorine
With 2ml (24.8 mmole) pyridine and 4.2ml (49.8 mmole) 2,4,6-three fluoro-triazines join in 5.0g (24.8 mmole) 2-(the amino-ethyl)-suspension of 6-chlorine apellagrin in the 125ml methylene dichloride.At ambient temperature, stir this reaction mixture then filtered in 3 hours.Solid is with the 50ml dichloromethane rinse and with twice of the freezing water washing of 60ml.Organic phase is at Na
2SO
4Upper drying, and vapourisation under reduced pressure solvent.Obtain the product of 5.01g orange oil form.Yield=99%.
1.3:N-methyl-cyanide yl acetamide
12.28ml (128.44 mmole) Vinyl chloroformate is added drop-wise to 10.0g (116.38 mmole) 99% cyanoacetic acid and 16.3ml (116.9 mmole) triethylamine being cooled in-30 ℃ the solution in the anhydrous THF of 100ml, then stirred 1 hour 30 minutes at-30 ℃.Drip subsequently 300ml with the saturated methyl alcohol of gaseous state methylamine, then stir at ambient temperature and spend the night.Vapourisation under reduced pressure solvent and product use methylene dichloride by filtering at silica gel: alcohol (95: 5) mixture wash-out carries out purifying.Obtain the product of 10.0g beige solid form.Fusing point=99 ℃.Yield=87%.
Method A (following 1.4 and 1.5 part).
1.4:3-[6-chloro-2-(ethylamino)-3-pyridyl]-2-cyano-3-hydroxy-n-methyl-2-acrylamide
With 60% sodium hydride of 3.98g (100 mmole) in mineral oil by aliquot join 9.80g (100 mmole) N-methyl cyano group-ethanamide being cooled in 0-5 ℃ the solution in the 100ml anhydrous dimethyl formamide.After releasing hydrogen gas finishes, stirred this mixture 10 minutes in envrionment temperature, and then it is cooled to 0-5 ℃.Then add 10.09g (49.8 mmole) 2-(amino-ethyl)-6-chloronicotinoyl fluorine in the 60ml dimethyl formamide solution and stir at ambient temperature this medium and spend the night.Add 2.85ml (49.8 mmole) acetic acid and vapourisation under reduced pressure volatile matter.Residue is dissolved in the water and this product methylene dichloride: then methyl alcohol (95: 5) mixture extraction uses ethyl acetate: THF (2: 1) mixture extraction for twice once.The organic phase that merges is used MgSO
4Carry out drying, then the vapourisation under reduced pressure solvent.Obtain the 19.0g product, this product former state is used for following step.
1.5:2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
110 ℃ of crude product (49.8 mmole) solution in the 600ml propyl carbinol of when step 7.4 finishes, obtaining of heating 19.0g 48 hours.The vapourisation under reduced pressure solvent also grinds the solid that obtains in methyl alcohol.Solid is dehydrated and dry in baking oven subsequently.Obtain the expectation product of the pale yellow solid form of 7.9g.Fusing point: 283-286 ℃.Yield=57%.
Method C (following 1.6 Partial Replacements 1.4 and 1.5 parts).
1.6:2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
60% sodium hydride of 0.394g (9.95 mmole) in mineral oil joined 0.483g (4.93 mmole) N-methyl-cyanide yl acetamide being cooled in 0-5 ℃ the solution in the 7ml anhydrous dimethyl formamide by aliquot.Under this temperature, continue to stir 10 minutes, then add 1.0g (4.93 mmole) 2-(the amino-ethyl)-solution of 6-chloronicotinoyl fluorine in the 5ml dimethyl formamide.Stir this medium in envrionment temperature and spend the night, then add again 0.197g (4.93 mmole) 60% sodium hydride by aliquot ground.Under this temperature, continue to stir and then added 0.56ml (9.78 mmole) acetic acid in 10 minutes.Add subsequently 60ml water and solid is dewatered, the water flushing is then dry in baking oven.Obtain 1.30g expectation product.Fusing point: 283-284 ℃.MH
+＝281。Yield=94%.
1H NMR (DMSO-d6,400MHz): δ 11.75 (s,＜1H, non-constant width); 11.00 (q, 1H, wide); (8.45 d, 1H); (8.10 s, 1H is wide); (7.40 d, 1H); (4.40 q, 2H); (2.80 d, 3H); (1.25 t, 3H).
1.7:2-amino-1-ethyl-7-(3-methyl-3-trimethyl silicane alcoxyl Ji-Ding-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
In 2 liters of three-necked flasks, with 40.7g2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-1,4-dihydro-[1,8] naphthyridines-3-methane amide (0.145 mole) and 56.2ml[(1,1-dimethyl-2-propynyl) oxygen] trimethyl silane (0.290mol) is incorporated in 365ml dimethyl formamide and the 365ml triethylamine mixture successively.Then added successively 0.983gCuI (5.16 mmole) and two (triphenylphosphine) palladium chlorides (II) (7.2 mmole) of 5.1g in 15 minutes with this reaction mixture of argon gas bubbling.Then reducing under the vacuum (vide r é duit) concentrated in 15 hours at 90 ℃ of these reaction mixtures of heating.Residue is dissolved in 500ml ethyl acetate/NaHCO
3(V/V=1/1) aqueous mixture and filter at the diatomite bolt washes with ethyl acetate.(then 3 * 50ml) extractions merge organic phase water, carry out drying through sodium sulfate, filter and concentrate under vacuum with methylene dichloride.Reacting coarse product (is used methylene dichloride: 80: 20 to 50: 50 gradient of ethylhexoate by chromatography on silica column, then methylene dichloride: 95: 5 to 90: 10 gradient elution of methyl alcohol) carry out purifying, obtain the desilylation product (yield=15.5%) that 36.2g expectation product (yield=62.3%) and 7.4g describe in next step.
1.8:2-amino-1-ethyl-7-(3-hydroxy-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
With 15g 2-amino-1-ethyl-7-(3-methyl-3-trimethyl silicane alcoxyl Ji-Ding-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (37.4 mmole) is dissolved in the 815ml tetrahydrofuran (THF).Solution is cooled to 0 ℃ then adds 13.0g 4-butyl ammonium fluoride trihydrate (41.2 mmole).Stirred at ambient temperature this reaction mixture 15 minutes.Be evaporated to dry doubling and residue is dissolved in ethyl acetate/tetrahydrofuran (THF)/water mixture.Then the water dichloromethane extraction merges organic phase, carries out drying through sodium sulfate, filters and concentrates under vacuum.Obtain the 15g crude product, it is dissolved under hot conditions in 1 liter of methyl alcohol, then adds the 6.75g gac and stirs this mixture 5 hours at 70 ℃.Behind diatomite filtration and vaporising under vacuum, obtain the expectation product of 11.9g white solid form.
Fusing point=255 ℃.MH
+＝329。Yield=82.9%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 11.75 (s,＜1H, non-constant width); 11.00 (q, 1H, wide); (8.40 d, 1H); 8.00 (s, 1H, wide); (7.40 d, 1H); 5.62 (s, 1H, wide); (4.4 q, 2H); (2.75 d, 3H); (1.45 s, 6H); (1.20 t, 3H).
■ embodiment 2:(±)-2-amino-1-ethyl-7-[(3-hydroxyl tetrahydrofuran-3-yl) ethynyl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (compound N is o.7)
2.1:(±)-3-ethynyl tetrahydrochysene-3-benzofuranol ((±)-3-é thynylt é trahydro-3-furanol)
With 3-oxo-tetrahydrofuran (4.97 mmoles; As at Tetrahedron 1991,47, describing ground among the 6975-6982 is prepared) solution in the 20ml tetrahydrofuran (THF) joins 0.5M ethynyl bromination magnesium that 20ml can commercial acquisition tetrahydrofuran (THF) (10 mmoles, being cooled in advance in 0 ℃ the solution in Aldrich).Then stirred at ambient temperature 4 hours and add NH
4The Cl saturated aqueous solution.Extract with ethyl acetate, then merge organic phase, with the washing of NaCl saturated aqueous solution, through dried over sodium sulfate, filter and under vacuum, concentrate.Behind purifying on the silica column, obtain (±)-3-ethynyl tetrahydrochysene of 319mg (2.79 mmole) yellow oil form-3-benzofuranol by chromatography, yield is 57%.
2.2:(±)-2-amino-1-ethyl-7-[(3-hydroxyl tetrahydrofuran-3-yl) ethynyl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
With 0.3g (2.24 mmole) 2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro [1,8] naphthyridines-3-methane amide at 17ml dimethyl formamide/triethylamine (V/V; 2/1) suspension in the mixture is positioned in the 10ml microwave tube.Then this suspension added 0.319g (2.79 mmole) (±)-3-ethynyl tetrahydrochysene-3-benzofuranol in 10 minutes successively with the argon gas bubbling, two (triphenylphosphine) palladium chlorides (II) (0.11 mmole) of 0.043g CuI (0.23 mmole) and 0.079g.
To seal that test tube is positioned in the microwave (CEM equipment, Discover type) and under pressure, then cool off and be evaporated to dried at 90 ℃ of these mixtures of heating 60 minutes (P=100W).Dissolve with ethyl acetate, organic phase is used NaHCO successively
3Then NaCl saturated aqueous solution washing of saturated aqueous solution through dried over sodium sulfate, is filtered and is concentrated under vacuum.The residue that obtains (is used methylene dichloride: 98: 2 to 95: 5 gradient elution of methyl alcohol) carry out purifying by the silicon-dioxide chromatography.Obtain the expectation product of the pale yellow solid form of 0.412g.
Fusing point=253 ℃.MH
+＝357。Yield=52%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 11.75 (s,＜1H, non-constant width); 11.00 (q, 1H, wide); (8.45 d, 1H); 8.00 (s, 1H, wide); (7.4 d, 1H); (5.6 d, 1H); (4.55-4.30 m, 3H); (3.95-3.80 m, 4H); (2.8 d, 3H); (2.20 m, 1H); (1.9-1.35 m, 8H); (1.25 t, 3H).
■ embodiment 3:(±)-2-amino-1-ethyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (compound N is o.8)
3.1: preparation (±)-1-methoxyl group-2-methyl-3-butyne-2-alcohol
1400 milliliters (0.7 moles) can the commercial solution of 0.5M ethynyl chlorination magnesium (ethynyl bromination magnesium) in tetrahydrofuran (THF) that obtains be poured in the three-necked flask under the argon gas.With ice bath solution is cooled to 2 ℃ and add at leisure the solution (heat release) of 30g (0.327mol) methoxy acetone in the 600ml tetrahydrofuran (THF).Then be poured over ice/NH in 1 hour 2 ℃ of stirrings
4On the Cl saturated aqueous solution mixture.Use extracted with diethyl ether, then merge organic phase, through dried over sodium sulfate, filter and under limited vacuum, concentrate.Obtain the expectation product (quantitative crude product yield) of 38g brown oil form, its purifying that does not carry out the back is used for next step.
3.2:(±)-2-amino-1-ethyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
With 3g (10.69 mmole) 2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro [1,8] naphthyridines-3-methane amide at 20ml DMF/Et
3N mixture (V/V; 1/1) suspension is positioned in the 80ml microwave tube.In this suspension, then added successively 1.83g (±)-1-methoxyl group-2-methyl-3-butyne-2-alcohol (16.03 mmole) in 10 minutes with the argon gas bubbling, two (triphenylphosphine) palladium chlorides (II) (0.53 mmole) of 0.081g CuI (0.43 mmole) and 0.375g.
To seal that test tube is positioned in the microwave oven (CEM equipment, Discover type) and 90 ℃ under pressure this mixture of heating 60 minutes (P=100W) then cool off and be evaporated to dried.Residue is dissolved in then uses 0.1N HCl solution washing in ethyl acetate/THF mixture.Organic phase is carried out drying through sodium sulfate, filters and concentrates under vacuum.
The residue that obtains carries out purifying (solid deposits by the silicon-dioxide chromatography; Use hexanaphthene: 30: 70 to 20: 80 gradient elution of ethylhexoate).Obtain the expectation product of the pale yellow solid form of 2.49g.
Product can carry out recrystallization in ethanol, in order to obtain white crystal.
Fusing point=211 ℃.MH
+＝358。Yield=65%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 11.75 (s,＜1H, non-constant width); 11.00 (q, 1H, wide); (8.45 d, 1H); 8.00 (s, 1H, wide); (7.4 d, 1H); (5.8 s, 1H); (4.4 q, 2H); (3.5-3.3 m+s, 5H); (2.8 d, 3H); (1.45 s, 3H); (1.2 t, 3H).
■ embodiment 4:(±)-2-amino-7-(3-cyclopentyl-3-hydroxyl third-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (compound N is o.10)
4.1:(±)-1-cyclopentyl third-2-alkynes-1-alcohol
0.87ml is encircled pentamethylene formaldehyde (8.15 mmoles; Aldrich) solution in the 10ml tetrahydrofuran (THF) joins that 18ml can commercial obtain be cooled in advance 0 ℃ (10 mmoles are in the 0.5M ethynyl bromination magnesium solution in Aldrich) at tetrahydrofuran (THF).Then stirred at ambient temperature 2 hours and add NH
4The Cl saturated aqueous solution.Extract with ethyl acetate, then merge organic phase, with the washing of NaCl saturated aqueous solution, through dried over sodium sulfate, filter and under vacuum, concentrate.(±)-1-cyclopentyl third-2-alkynes of acquisition 0.931g shallow brown oil form-1-alcohol, yield is 92%.
4.2:(±)-2-amino-7-(3-cyclopentyl-3-hydroxyl third-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
With 1g (3.56 mmole) 2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro [1,8] naphthyridines-3-methane amide at 25ml dimethyl formamide/triethylamine (V/V; 2.5/1) suspension in the mixture is positioned in the 10ml microwave tube.In this suspension, then added successively 0.931g (7.5 mmole) (±)-1-cyclopentyl third-2-alkynes-1-alcohol, 0.068g CuI (0.36 mmole) and two (triphenylphosphine) palladium chlorides (II) (0.18 mmole) of 0.125g in 10 minutes with the argon gas bubbling.
To seal test tube be positioned in the microwave oven (CEM equipment, Discover type) and under pressure 80 ℃ the heating these mixtures 17 minutes (P=50W).Be evaporated to driedly, then residue be dissolved in the ethyl acetate.Organic phase is used NaHCO successively
3Then NaCl saturated aqueous solution washing of saturated aqueous solution through dried over sodium sulfate, is filtered and is concentrated under vacuum.The residue that obtains (is used methylene dichloride: 98: 2 to 95: 5 gradient elution of methyl alcohol) carry out purifying by the silicon-dioxide chromatography.Obtain the expectation product of the pale yellow solid form of 0.73g.
Fusing point=253 ℃.MH
+＝369。Yield=56%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 11.75 (s,＜1H, non-constant width); 11.00 (q, 1H, wide); (8.45 d, 1H); 8.00 (s, 1H, wide), 7.45 (d, 1H); (6.05 s, 1H); (4.4 q, 2H); (3.95-3.80 m, 4H); (2.8 d, 3H); (2.35-2.10 m, 2H); (1.45 s, 3H); (1.25 t, 3H).
■ embodiment 5:(±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(pyridine-2-ylmethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (compound N is o.47)
5.1:6-chloro-2-[(pyridine-2-ylmethyl) amino] nicotinic acid
With 4g 2, (20.83 mmoles Aldrich) are positioned in the 80ml sealing test tube that comprises the 40ml trimethyl carbinol with 10.74ml 2-(amino methyl) pyridine (104.17 mmole) the 6-dichloro-nicotinic acid.100 ℃ of heated overnight and be evaporated to dried.Residue is dissolved in the water and by pouring 10% acetic acid aqueous solution into carries out acidifying.By filtering separation precipitation, and in the baking oven under the vacuum that reduces after the drying, obtain the expectation product of 4.35g yellow powder form.(yield=79%).
5.2:6-chloro-2-[(pyridine-2-ylmethyl) amino] the nicotinoyl fluorine
With 2.27ml triethylamine (16.31 mmole) and 1.65ml 2,4,6-, three Cyanuric trifluorides (19.57 mmole) are added to 4.3g 6-chloro-2-[(pyridine-2-ylmethyl successively) amino] in the suspension of nicotinic acid (16.31 mmole) in the 90ml methylene dichloride.Stir at ambient temperature this mixture and then added methylene dichloride/freezing water mixture in 1 hour.Organic phase is with ice-cold NaHCO
3Solution washing 3 times is then through Na
2SO
4Drying is filtered and is concentrated under vacuum.Obtain the expectation product of 3.97g orange solids form.Yield=92%.
5.3:2-amino-7-chloro-N-methyl-4-oxo-1-(pyridine-2-ylmethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
By aliquot ground 60% sodium hydride of 1.12g (28.06 mmole) in mineral oil joined in the solution of 1.31g (13.36 mmole) N-methyl cyano group-ethanamide (being prepared according to 1.3) in the 20ml anhydrous dimethyl formamide that is cooled to 0-5 ℃.Then added 3.55g (4.93 mmole) 6-chloro-2-[(pyridine-2-ylmethyl in ten minutes in continuation stirring under this temperature) amino] solution of nicotinoyl fluorine in the 20ml dimethyl formamide.Stirring at ambient temperature this medium spends the night then by aliquot ground (par fracitons) adding 0.561g (14.03 mmole) 60% sodium hydride.Under this temperature, continue to stir 1 hour, and then this reaction mixture was poured on ice and is acidified to pH5-6 with 10% acetic acid aqueous solution.By the filtering separation precipitation, and in baking oven, after the drying, obtain the expectation product of 3.98g beige solid form.MH
+＝344。Yield=87%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 9.20 (s,＜1H, non-constant width); (8.85 s, 1H); (8.30 m, 1H); 8.10-7.85 (m, 2H, wide); (7.80 d, 1H); 7.75 (s, 1H, wide); (6.90 d, 1H); (4.90 s, 2H); (2.95 s, 3H).
5.4:(±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(pyridine-2-ylmethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-carboxamide hydrochloride
With 1g 2-amino-7-chloro-N-methyl-4-oxo-1-(pyridine-2-ylmethyl)-1,4-dihydro-1, the suspension of 8-naphthyridines-3-methane amide (2.91 mmole) in the mixture of 20ml dimethyl formamide and 5.7ml triethylamine is positioned in the 80ml microwave tube.In this suspension, then add successively 0.498g (±)-1-methoxyl group-2-methyl-3-butyne-2-alcohol (4.36 mmole) with the argon gas bubbling, two (triphenylphosphine) palladium chlorides (II) (0.15 mmole) of 0.055gCuI (0.29 mmole) and 0.102g.
The sealing test tube is positioned over microwave oven (CEM equipment, Discover type) and under pressure, then cools off and be evaporated to dried at 80 ℃ of these mixtures of heating 45 minutes (P=100W).Residue is dissolved in ethyl acetate and the water.Then water merges organic phase with ethyl acetate extraction (3 times), carries out drying through sodium sulfate, filters and concentrates under vacuum.
The residue that obtains carries out purifying (solid deposits by the silicon-dioxide chromatography; Use CH
2Cl
2/ MeOH/NH
498/2/0.2 to 95/5/0.5 gradient elution of the OH aqueous solution).After in ether, grinding, obtain the expectation product of 0.425g yellow solid form.
Fusing point=169 ℃.MH
+＝422。Yield=35%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 11.65 (s,＜1H, non-constant width); 11.00 (q, 1H, wide); (8.50-8.35 m, 2H); 8.00 (s, 1H, wide); (7.75 ddd, 1H); (7.45-7.20 m, 3H); 5.80 (s, 2H, wide); (5.70 s, 1H); (3.45-3.25 m+s, 5H); (2.80 d, 3H); (1.40 s, 3H).
■ embodiment 6:(±)-2-amino-1-ethyl-7-(3-hydroxyl-3-pyrazine-2-Ji Ding-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (compound N is o.48)
6.1:(±)-2-pyrazine-2-Ji Ding-3-alkynes-2-alcohol
0.5M the solution of ethynyl chlorination magnesium in tetrahydrofuran (THF) (31.90 mmole Aldrich) dilutes with the 50ml tetrahydrofuran (THF) and then is cooled to 0 ℃.Then (24.56 mmoles Lancaster) and at 0 ℃ stirred this mixture 4 hours to add several times the basic ethyl ketone of 3g 1-pyrazine-2-.Again cool off this mixture and add at leisure NH with ice bath
4The Cl aqueous solution.With ethyl acetate extraction twice, then merge organic phase, through dried over sodium sulfate, filter and under limited vacuum, concentrate.The oily residue that obtains carries out purifying, the expectation product (yield=80%) of acquisition 2.9g yellow oil form by silicon-dioxide chromatography (use hexanaphthene: ethylhexoate, 70: 30 to 50: 50 gradient elutions).
6.2:(±)-2-amino-1-ethyl-7-(3-hydroxyl-3-pyrazine-2-Ji Ding-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
With 1g (3.56 mmole) 2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro [1,8] naphthyridines-3-methane amide at 25ml DMF/Et
3N (V/V; 2.5/1) suspension in the mixture is positioned in the 10ml microwave tube.In this suspension, then added successively 0.792g (±)-2-pyrazine-2-Ji Ding-3-alkynes-2-alcohol (5.34 mmole) in 10 minutes with the argon gas bubbling, two (triphenylphosphine) palladium chlorides (II) (0.18 mmole) of 0.068g CuI (0.36 mmole) and 0.125g.
The sealing test tube is positioned over microwave oven (CEM equipment, Discover type) and under pressure, heats these mixtures 2 * 45 minutes (P=50W) at 80 ℃.After turning back to envrionment temperature, be evaporated to dried then residue and dissolve with ethyl acetate.Organic phase is used NaHCO successively
3Then NaCl saturated aqueous solution washing of saturated aqueous solution through dried over sodium sulfate, is filtered and is concentrated under vacuum.The residue that obtains carries out purifying by silicon-dioxide chromatography (use methylene dichloride: methyl alcohol, 100: 0 to 98: 2 gradient elution).Obtain the impure expectation product of 0.2g brown solid.Carry out further purifying by chromatography (use hexanaphthene: ethylhexoate, 20: 80 to 0: 100 gradient elutions) on silica column, obtain at last the expectation product of 0.068g yellow solid form.
Fusing point=271 ℃.MH
+＝393。Yield=4.9%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 11.75 (s,＜1H, non-constant width); 11.00 (q, 1H, wide); (9.0 s, 1H); (8.65 m, 1H); (8.40 d, 1H); 8.00 (s, 1H, wide); (7.40 d, 1H); (6.85 s, 1H); (4.4 q, 2H); (2.75 d, 3H); (1.80 s, 3H); (1.20 t, 3H).
■ embodiment 7:(±)-2-amino-7-(3-cyclopropyl-3-hydroxyl-4-methoxyl group fourth-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (compound N is o.50)
7.1:(±)-2-cyclopropyl-1-methoxyl group fourth-3-alkynes-2-alcohol
7.1.1:N-methoxyl group-N-methyl-2-methoxyl acetamide
With 35.96ml triethylamine (258 mmole), then the solution of 14g methoxyacetyl chloride (Aldrich, 129 mmoles) in the 250ml methylene dichloride joins N-methyl-MHX hydrochloride in 250ml is cooled to solution in 0 ℃ the methylene dichloride.Stirring this mixture made it be back to envrionment temperature in 3 hours simultaneously.The HCl aqueous solution of adding 1N then organic phase washes with water, through dried over sodium sulfate, filters also concentrated under vacuum.Obtain the expectation product of 13.14g oil form, it uses (crude product yield=76%) without purifying subsequently.
7.1.2:1-methoxyl group-4-(trimethyl silyl) fourth-3-alkynes-2-ketone
Make the solution of 14.75ml trimethyl silyl acetylene (103.62 mmole) in the 250ml tetrahydrofuran (THF) be cooled to-70 ℃ then add 64.76ml 1.6M just-solution of BuLi (103.62 mmole) in hexane.Then added fast the 13.14g N-methoxyl group-solution of N-methyl-2-methoxyl acetamide (98.69 mmole) in the 250ml tetrahydrofuran (THF) in 25 minutes-70 ℃ of stirrings.During adding, temperature is raised to-50 ℃, then removes cryostat (bain froid) and stirs at ambient temperature this mixture 2 hours.Add the 1N HCl aqueous solution and then use ethyl acetate extraction 4 times.Merge organic phase, carry out drying through sodium sulfate, filter and under vacuum, concentrate.1-methoxyl group-4-(trimethyl silyl) fourth of acquisition 13.4g shallow brown oil form-3-alkynes-2-ketone, it uses (crude product yield=80%) without purifying subsequently.
7.1.3:(±)-2-cyclopropyl-1-methoxyl group-4-(trimethyl silyl) fourth-3-alkynes-2-alcohol
(26.43 mmoles Aldrich) join in 3g 1-methoxyl group-4-(trimethyl silyl) fourth-solution of 3-alkynes-2-ketone (17.62 mmole) in the 160ml ether with 52.85ml 0.5M cyclopropyl bromination magnesium.Stir at ambient temperature this mixture overnight, then water/ice bath cools off and adds NH
4The Cl aqueous solution and ethyl acetate.Then mixture ethyl acetate extraction 3 times merge organic phase, through dried over sodium sulfate, filter also concentrated under vacuum.The oil residue carries out purifying by chromatography at silica column, wherein use hexanaphthene: 100: 0 to 80: 20 gradient of ethylhexoate is carried out wash-out, (±)-2-cyclopropyl of acquisition 1.9g oil form-1-methoxyl group-4-(trimethyl silyl) fourth-3-alkynes-2-alcohol, yield is 51%.
7.1.4:(±)-2-cyclopropyl-1-methoxyl group fourth-3-alkynes-2-alcohol
10.9mg salt of wormwood (0.08 mmole) is joined in 1.67g (±)-2-cyclopropyl-1-methoxyl group-4-(trimethyl silyl) fourth-3-alkynes-2-alcohol (7.86 mmole) solution in methyl alcohol, and stir at ambient temperature this mixture overnight.Evaporate methyl alcohol, and dissolve with ethyl acetate/water mixture.With ethyl acetate extraction 3 times, then merge organic phase, through dried over sodium sulfate, filter also concentrated under vacuum.(±)-2-cyclopropyl of acquisition 0.434g oil form-1-methoxyl group fourth-3-alkynes-2-alcohol, it uses (crude product yield=40%) without purifying subsequently.
7.2:(±)-2-amino-7-(3-cyclopropyl-3-hydroxyl-4-methoxyl group fourth-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
0.47g (1.68 mmole) 2-amino-7-chloro-1-ethyl-N-methyl-suspension of 4-oxo-Isosorbide-5-Nitrae-dihydro [1,8] naphthyridines-3-methane amide in 8.4ml dimethyl formamide and 3ml triethylamine mixture is positioned in the 10ml microwave tube.In this suspension, then added successively 0.433g (±)-2-cyclopropyl-1-methoxyl group fourth-3-alkynes-2-alcohol (3.09 mmole) in 10 minutes with the argon gas bubbling, two (triphenylphosphine) palladium chlorides (II) (0.08 mmole) of 0.032gCuI (0.17 mmole) and 0.059g.
To seal test tube and be positioned in the microwave oven (CEM equipment, Discover type), and under pressure, then cool off and be evaporated to dried at 80 ℃ of these mixtures of heating 30 minutes (P=50W).Residue dissolves with ethyl acetate again, and organic phase is used NaHCO successively
3Then NaCl saturated aqueous solution washing of saturated aqueous solution through dried over sodium sulfate, is filtered and is concentrated under vacuum.The residue that obtains carries out purifying by the silicon-dioxide chromatography, and wherein use methylene dichloride: 100: 0 to 97: 3 gradient of methyl alcohol is carried out wash-out.After in ether, grinding and filtering, obtain the expectation product of 0.316g light yellow solid form.
Fusing point=208 ℃.MH
+＝385。Yield=49%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 11.75 (s,＜1H, non-constant width); 11.00 (q, 1H, wide); (8.45 d, 1H); 8.00 (s, 1H, wide); (7.40 d, 1H); (5.60 s, 1H); (4.4 q, 2H); (3.50 s, 2H); (3.40 s, 3H); (2.75 d, 3H); (1.20 t, 3H); (0.6-0.3 m, 4H).
■ embodiment 8:(±)-2-amino-1-cyclopentyl-7-(3,4-dihydroxyl-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide (compound N is o.53)
8.1:(±)-2-methyl fourth-3-alkynes-1, the 2-glycol
Can the commercial solution of 0.5M ethynyl chlorination magnesium in tetrahydrofuran (THF) that obtains dilute with the 200ml tetrahydrofuran (THF) and then be cooled to 0 ℃.Then add oxyacetone in the 200ml tetrahydrofuran (THF) solution and stirred at ambient temperature 3 hours.Cool off this reaction mixture and then add NH
4The Cl aqueous solution.With ethyl acetate extraction 3 times, then merge organic phase, through dried over sodium sulfate, filter also lower concentrated in vacuum (about 200 millibars).At last, obtain the expectation product of 20g brown oil form, it uses (quantitative crude product yield) without purifying subsequently.
(8.2:2-amino cyclopentyl)-6-chlorine apellagrin
With 15g 2, (70.31 mmoles Aldrich) are positioned in the sealing test tube that comprises the 40ml trimethyl carbinol with 34.7ml cyclopentamine (351.56 mmole) the 6-dichloro-nicotinic acid.Heat these mixture overnight and be evaporated to dried at 100 ℃.Residue is dissolved in the water, and carries out acidifying in 10% acetic acid aqueous solution by toppling over, then use chloroform extraction.Merge organic phase, carry out drying through sodium sulfate, filter and under vacuum, concentrate.Solid residue grinds in ether/pentane admixture, obtains the expectation product (yield=29.5%) of 5g pale solid form.
(8.3:2-amino cyclopentyl)-6-chlorine acyl fluorides
With 0.34ml (4.15 mmole) pyridine and 0.53ml (6.23 mmole) 2,4,6-three fluoro-triazines join in 1.0g (4.15 mmole) 2-(the amino cyclopentyl)-suspension of 6-chlorine apellagrin in the 12ml methylene dichloride.Stir at ambient temperature this mixture then diluted with methylene dichloride in 2 hours.Organic phase is with ice-cooled NaHCO
3Twice of solution washing is then through Na
2SO
4Carry out drying, filter and under reduced pressure concentrate.Obtain the product of 1g brown oil form, it is directly used in next step.Quantitative crude product yield.
Method A (hereinafter 8.4 parts).
8.4:3-[6-chloro-2-(cyclopentyl is amino)-3-pyridyl]-2-cyano-3-hydroxy-n-methyl-2-acrylamide+2-amino-7-chloro-1-cyclopentyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
With 0.349g (8.72 mmole) sodium hydride (in mineral oil, 60%) by join in a small amount 0.427g (4.36 mmole) N-methyl cyano group-ethanamide (describe is prepared) being cooled in 0-5 ℃ the solution in the 10ml dry DMF in 1.3.After no longer including hydrogen and emitting, stirred at ambient temperature this mixture 10 minutes, and then be cooled to 0-5 ℃.Then add 1.0g (4.15 mmole) 2-(the amino cyclopentyl)-solution of 6-chloronicotinoyl fluorine in 10ml DMF and stirred at normal temperatures this medium 1 hour.Add 60% sodium hydride of 0.174mg (4.35 mmole) in mineral oil, stir at ambient temperature this mixture overnight.Reaction mixture is poured on ice/0.1N HCl aqueous mixture and by filtering separation precipitates.In water flushing with in baking oven after the drying, obtain 1.2g light green solid, it is by 3-[6-chloro-2-(cyclopentyl is amino)-3-pyridyl]-2-cyano-3-hydroxy-n-methyl-2-acrylamide and 2-amino-7-chloro-1-cyclopentyl-N-methyl-4-oxo-1,4-dihydro-1,2/1 mixture of 8-naphthyridines-3-methane amide consists of.
Method B (hereinafter 8.5 parts).
8.5:2-amino-7-chloro-1-cyclopentyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
Can the commercial 1.0M potassium tert.-butoxide that obtains at tetrahydrofuran (THF) (7.48 mmoles; Aldrich) solution in joins 1.2g and describes in 8.4 in the solution of mixture (3.74 mmole) in the 40ml anhydrous tetrahydro furan.Stir at ambient temperature this mixture and then added the 0.1NHCl aqueous solution in 15 minutes, and with twice in this mixture of ethyl acetate extraction.Organic phase is carried out drying through sodium sulfate, filters and concentrates under vacuum.In ether, grind and in baking oven, after the drying, obtain the expectation product (yield=44%) of 0.53g yellow solid form.Fusing point=256-258 ℃.MH
+＝321。
8.6:(±)-2-amino-1-cyclopentyl-7-(3,4-dihydroxyl-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
In the 500ml three-necked flask, with 15g 2-amino-7-chloro-1-cyclopentyl-N-methyl-4-oxo-1,4-dihydro [1,8]-and naphthyridines-3-methane amide (53.44 mmole) and 11.11g (±)-2-methyl fourth-3-alkynes-1,2-glycol (83.39 mmole) is incorporated in 267ml dimethyl formamide and the 104ml triethylamine successively.In this reaction mixture, use argon gas bubbling 15 minutes, then add successively two (triphenylphosphine) palladium chlorides (II) (2.67 mmole) of 1.02g CuI (5.34 mmole) and 1.87g.Concentrated under the vacuum that then 100 ℃ of these reaction mixtures of heating were reducing in 30 minutes.Be dissolved in residue in the chloroform/water mixture and leach insoluble material.Obtain the 20g solid, it carries out purifying (then dissolving uses the solid deposits behind 99: 1 to 80: 20 gradient elutions of methylene chloride/methanol in the tetrahydrofurfuryl carbinol mixture) by the silicon-dioxide chromatography, obtains the expectation product of 7.5g beige solid form.
Fusing point=210.5 ℃.MH
+＝385。Yield=42%.
1H NMR (DMSO-d6,400MHz, δ (ppm)): δ 11.6 (s,＜1H, non-constant width); 11.05 (q, 1H, wide); (8.40 d, 1H); (7.35 d, 1H); (5.5 s, 1H); (5.15 m, 1H); (5.0 t, 1H); (3.45 m, 2H); (2.80 d, 3H); (2.3-2.1 m, 4H); (2.05-1.8 m, 2H); (1.75-1.5 m, 2H); (1.4 s, 3H).
Show below illustrated according to chemical structure and the physical properties of formulas more of the present invention (I) compound.In this table:
-asterisk " * " expression is (at R
1And R
2Form together in ring (heterocycle or cycloalkyl) situation) by its carbon that described ring is connected with the adjacent carbons of acetylene bond,
-Me and Et represent methyl and ethyl respectively,
-in " salt " hurdle, the compound of " " expression free alkali form, and the compound of " HCl " expression hydrochloride form,
-PF hurdle represent this compound fusing point (℃) and
-on the CL/SM hurdle, successively expression, the employed high efficiency liquid phase chromatographic analysis method that is discussed in more detail below (A, B or C), the retention time of this compound (minute) and the MH by Mass Spectrometric Identification
+Peak value.
. method A:
Post: Kromasil, 50 * 2.1mm, 3.5 μ m
Solvent orange 2 A: H
2O/ACN/TFA (1000/30/0.5); Solvent B:ACN/TFA (1000/0.5); Flow velocity=0.5ml/ minute
Gradient: 100/0 (0 minute) to 0/100 (12 minutes) are to 0/100 (15 minutes)
Detect: 220nM
Ionization: ESI+
. method B:
Post: Gemini, 50 * 3mm, 3 μ m
Solvent orange 2 A: H
2O+0.1%HCO
2H; Solvent B:ACN+0.1%HCO
2H; Flow velocity=1ml/ minute
Gradient: 95/5 (0 minute) to 0/100 (5.5 minutes) are to 0/100 (7.5 minutes)
Detect: 220nM
Ionization: ESI+
. method C:
Post: Kromasil, 50 * 2.1mm, 3.5 μ m
Solvent orange 2 A: CH
3CO
2NH
45mM; Solvent B:ACN; Flow velocity=0.5ml/ minute
Gradient: 100/0 (0 minute) to 0/100 (13 minutes) are to 0/100 (16 minutes)
Detect: 220nM
Ionization: ESI+
-in chirality CL hurdle, for optically pure compound (enantiomerism purity＞95%), next coming in order represent and employed HPLC (high performance liquid chromatography) described in detail below (D or E), and the retention time of compound (minute).
. method D:
Post: Chiralpak AD-H, 250 * 4.6mm, 5 μ M
Solvent orange 2 A: 2-propyl alcohol/TFA (1000/1); Solvent B: heptane/2-propyl alcohol (1000/30)
Permanent solvent: 50%A+50%B
Flow velocity: 0.8ml/ minute
Detect: 220nM
. method E:
Post: Chiralpak AD-H, 250 * 4.6mm, 5 μ M
Solvent orange 2 A: 2-propyl alcohol/TFA (1000/1); Solvent B: heptane/2-propyl alcohol (1000/30)
Permanent solvent: 20%A+80%B
Flow velocity: 0.8ml/ minute
Detect: 220nM
-in the chirality hurdle, "/" is non-chiral compound, (±) is the compound of racemic mixture form, and (-) is the compound (enantiomerism purity＞95%) of optically pure left-handed enantiomer (enantiomerism purity＞95%) and (+) optically pure dextrorotation enantiomer form.In optically pure compound situation, the value of opticity is 20 ℃ of measurements (wherein in bracket, the concentration c of this compound and the solvent of use).
In order to obtain optically pure enantiomer, make corresponding racemic mixture stand to use the preparative chromatography of chirality static phases to separate (Chiralpak AD-H post, 250 * 21mm, 5mm), it uses following as moving phase:
. or CO
2/ 2-propyl alcohol (70%/30%), flow velocity be 60ml/ minute under 100bar pressure
. or having isohexane/ethanol (70/30) mixture of 0.3%TFA, flow velocity is 120ml/ minute.
After wash-out and evaporation, separate every kind of enantiomer, every kind chemical purity and enantiomerism purity are measured by analytical method known to those skilled in the art.
Table
Compound according to the present invention is as the object of pharmacology test, and this test can be measured them to VEGFR-3 enzymeinhibition effect.
Measure the tyrosine kinase activity of VEGFR-3 by ELISA
The enzymic activity of VEGFR-3 uses the ELISA test to estimate by the intensity of measuring the phosphorylation of gathering the Glu-Tyr substrate.The effect of this product is undertaken quantitatively by the concentration (IC50) that reduces enzyme gross activity 50%.For the mensuration of IC50 value, product is diluted among the DMSO, have the concentration range of 3-1000nM.In the day before yesterday of this operation, (250 μ g/ml do not contain Ca in 1xPBS with the poly-Glu-Tyr substrate of 125 μ l
2+Or Mg
2+Or sodium bicarbonate) (for example, the elisa plate in SIGMAProtein Tyrosine Kinase Assay work box is in each hole Ref.PTK-101) to be placed on elisa plate.This plate covers with adhesive film subsequently and is incubated overnight at 37 ℃.Second day, by upset with described hole turned letter, by add the washing of 300 μ l buffered soln (PBS+0.05%Tween20) and by 37 ℃ again this plate of incubation carried out drying in 2 hours.90 microlitre reaction mixtures are placed in each hole.This mixture comprises 1X kinase buffer liquid, has added the inhibitor of 30 μ M ATP and expectation concentration in this damping fluid.Add subsequently the VEGFR-3-TK without ATP (Cell Signaling, Ref.7790) of 20 μ l beforehand dilutions in kinase buffer liquid (except negative control wells (puits
N é gatif) outside, in this hole, adds 20 μ l without the damping fluid of enzyme).This plate carried out incubation 30 minutes simultaneously in mild stirring subsequently at ambient temperature.Carry out 3 flushings with buffered soln (washing 300 μ l/ holes) at every turn after, join 100 μ l antiphosphotyrosine antibody-HRP (1/30000) in each hole and simultaneously carried out again incubation 30 minutes in mild stirring at ambient temperature.Wash 3 times in buffered soln (at every turn washing 300 μ l/ holes) after, the phosphorylation of substrate is by adding every hole 100 μ l OPD substrates, and 1OPD tablet and 1 urea tablet (in 20ml water) (temporarily preparation under lucifuge) show.Incubation is after 7 minutes at ambient temperature and under lucifuge, and this reaction is by adding every hole 100 μ l 1.25M (2.5N) H
2SO
4Stop and reading absorbancy at 492nm.Gross activity is by estimating (stimulation) and the difference of carrying out the optical density(OD) that the sample of incubation obtains when not having VEGFR-3 (non-stimulation) in the presence of VEGFR-3.
Compound exhibits according to the present invention is lower than the IC50 value of 10 μ M, and major part is lower than 1 μ M.For instance, the IC50 value of some compound of table 1 shows in the following Table 2.
Table 2
| The numbering (table 1) of compound | Cl50(nM) |
| 2 | 23 |
| 3 | 46 |
| 11 | 37 |
| 12 | 21 |
| 16 | 257 |
| 24 | 6 |
| 37 | 34 |
| 46 | 40 |
| 47 | 65 |
| 60 | 43 |
| 62 | 14 |
| 70 | 5 |
| 72 | 23 |
| 80 | 2 |
| 81 | 38 |
Therefore be apparent that, compound according to the present invention has the VEGFR-3 enzymeinhibition active; They therefore can be for the preparation of medicine, especially the inhibition medicine of VEGFR-3.
Therefore, according to it on the other hand, the objective of the invention is medicine, it comprises formula (I) compound, or the additive salt of the latter and pharmaceutically acceptable acid or alkali, or hydrate or solvate, and enantiomer or diastereoisomer (mixture that comprises formula (I) compound here).
Another aspect of the present invention comprises at least a combination according to compound of the present invention and at least a chemotherapeutics.
Especially, compound of the present invention can use individually or as the mixture with at least a chemotherapeutics, and described chemotherapeutics can be selected from:
Alkylating agent,
Intercalating agent,
Antiseptic-germicide,
Antimitotic agent,
Antimetabolite,
Antiproliferative,
Microbiotic,
Immunomodulator,
Antiphlogistic,
Kinase inhibitor,
Anti-angiogenic agent,
Anti-angiogenic dose (antivasculaires),
Female hormone and male hormone,
Prodrug with above-mentioned dose or derivative.
Compound according to the present invention can also be combined with radiation therapy.
Compound of the present invention and above-mentioned chemotherapeutics and/or the combination of radiation are another object of the present invention.
Above-mentioned chemotherapeutics and/or radiation can side by side, dividually or sequentially administrations.Treatment will be regulated according to patient to be treated by the practitioner.
These medicines can be used for the treatment of use, are used for the treatment of especially and/or prevent:
-cancer and its transfer, as: glioblastoma, multiple myeloma, myelodysplastic syndrome, Kaposis sarcoma, the skin heart sarcoma, noumenal tumour, lymphoma, melanoma, mammary cancer, colorectal carcinoma, lung cancer, comprise non-small cell carcinoma (cancers non à petites cellules), carcinoma of the pancreas, prostate cancer, kidney, the incidence cancer, liver cancer, ovarian cancer, respiratory tract and chest organ cancer (cancers de l ' appareil respiratoire et thoracique), or the tumour of other VEGF expression R-3 or relate to that blood vessel occurs or the tumour of lymphatic vessel generative process.
-non-tumor proliferation disease and the pathology blood vessel relevant with VEGFR-3 occurs, such as joint disease, restenosis, psoriasis, vascular tumor, lymphangioma, glaucoma, glomerulonephritis, diabetic nephropathy, nephrosclerosis, thrombotic microangiopathy syndrome (syndromesmicroangiopathiques thrombotiques), liver cirrhosis, atherosclerosis, organ-graft refection, relate to that blood vessel occurs or the illness in eye of lymphatic vessel generative process, such as diabetic retinopathy or macular degeneration.
-also or be used for the treatment of and prevent because the inflammation of infected by microbes and autoimmune disease generation (chronic or non-chronic), such as polyarthritis destruens.
-also or be used for the treatment of rare disease, such as LAM.
According to another aspect of the present invention, the present invention relates to pharmaceutical composition, it comprises compound according to the present invention as activeconstituents.These pharmaceutical compositions comprise at least a according to compound of the present invention of effective dose, or pharmacologically acceptable salt, the hydrate of described compound or solvate, and at least a pharmaceutically acceptable vehicle.
According to medicament forms and expectation medication, described vehicle is selected from vehicle known to those skilled in the art.
Within being used for oral, hypogloeeis, subcutaneous, intramuscular, intravenously, body surface, part, tracheae, in the nose, through the pharmaceutical composition of the present invention of skin or rectal administration, above the activeconstituents of formula (I) or its optional salt, solvate or hydrate can with the unit form of medication with the form of mixtures of traditional drug excipient to animal and human's class and administration with treatment or prevent above-mentioned obstacle or disease.
Suitable unit form of medication comprises and passes through oral route, such as tablet, soft or hard capsule, powder, particle and oral liquid or suspension, the hypogloeeis, contain in the clothes, tracheae, intraocular or intranasal administration form, by suction, body surface, through skin, subcutaneous, intramuscular or intravenous form of medication, rectal administration form and implant.Use for body surface, can use with emulsifiable paste, gel, ointment or washing lotion according to compound of the present invention.
For instance, the unit form of medication according to compound of the present invention of tablet form can comprise following component:
According to compound 50.0mg of the present invention
N.F,USP MANNITOL 223.75mg
Croscarmellose sodium 6.0mg
W-Gum 15.0mg
Vltra tears 2.25mg
Magnesium Stearate 3.0mg
According to a further aspect of the invention, it also relates to the method for the treatment of symptom as noted above, it comprise to patient's administration effective dose according to compound of the present invention, or a kind of in its pharmacologically acceptable salt or its hydrate or its solvate.
Claims (23)
1. the compound of formula (I):
Wherein
R
1
And R
2
(1)Independently of one another expression:
. perhaps hydrogen atom,
. perhaps C1-C7 alkyl or C3-C8 cycloalkyl, wherein said alkyl and cycloalkyl are randomly replaced by one or more groups that are selected from hydroxyl and C1-C4 alkoxyl group,
. perhaps randomly with one or more phenyl that are selected from following group replacement: C1-C4 alkyl, C1-C4 alkoxyl group or hydroxyl,
. perhaps comprise 5 or 6 chain links and comprise one or more heteroatomic aryl that are selected from nitrogen, oxygen and sulphur,
(2) or R
1And R
2Form with the carbon atom that carries them:
.C4-C8 cycloalkyl,
R
3
Representative:
. the perhaps C1-C7 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: hydroxyl or C1-C4 alkoxyl group,
. perhaps-(CH
2)
n-heterocyclic group, n=0 or 1 wherein, and wherein this heterocyclic group comprises 4-8 chain link and comprises the heteroatoms that at least one is selected from N, O and S atom,
. perhaps-(CH
2)
n-heteroaryl, n=0 or 1 wherein, wherein this heteroaryl comprises 5 or 6 chain links and comprises one or more heteroatomss that are selected from nitrogen, oxygen and sulphur;
R4 representsHydrogen atom or C1-C4 alkyl,
For alkali or with the additive salt form of acid, and its enantiomer, diastereoisomer, and their mixture.
2. according to claim 1 formula (I) compound is characterised in that
R
1
And R
2
(1) independently of one another representative:
. perhaps hydrogen atom,
. perhaps C1-C4 alkyl or C3-C8 cycloalkyl, wherein said alkyl randomly replace with one or more groups that are selected from hydroxyl and C1-C4 alkoxyl group,
. the phenyl that perhaps randomly replaces with one or more groups that are selected from the C1-C4 alkoxyl group,
. perhaps comprise 5 or 6 chain links and comprise one or more heteroatomic aryl that are selected from nitrogen, oxygen and sulphur,
(2) or R
1And R
2Form with the carbon atom that carries them:
.C4-C8 cycloalkyl,
R
3
Representative:
. the perhaps C1-C4 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: the C1-C4 alkoxyl group,
. perhaps-(CH
2)
n-heterocyclic group, wherein n=0 or 1 and wherein this heterocyclic group comprise 4-8 chain link and comprise the heteroatoms that at least one is selected from N and O atom,
. perhaps-(CH
2)
n-heteroaryl, wherein n=0 or 1 and wherein this heteroaryl comprise 5 or 6 chain links and comprise one or more nitrogen heteroatoms;
R 4 RepresentativeThe C1-C4 alkyl;
For alkali or with the additive salt form of acid, and its enantiomer, diastereoisomer, and their mixture.
3. according to claim 1 formula (I) compound is characterised in that
R
1
And R
2
(1) independently of one another representative:
. perhaps hydrogen atom,
. perhaps C1-C4 alkyl or C3-C8 cycloalkyl, wherein said alkyl randomly replace with one or more groups that are selected from hydroxyl and C1-C4 alkoxyl group,
. the phenyl that perhaps randomly replaces with one or more C1-C4 alkoxyl groups,
. perhaps 5-or 6-the unit heteroaryl, it is selected from pyridyl, furyl, thienyl, pyrimidyl, pyrazinyl and thiazolyl,
(2) or R1 and R2 form with the carbon atom that carries them:
.C4-C8 cycloalkyl,
R
3
Representative:
. the perhaps C1-C4 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly are selected from following group and replace with one or more: the C1-C4 alkoxyl group;
. perhaps-(CH
2)
n-heterocyclic group, n=0 or 1 wherein, wherein this heterocyclic group comprises 4-8 chain link and comprises the heteroatoms that at least one is selected from the O atom,
. perhaps-(CH
2)
n-heteroaryl, wherein n=1 and wherein this heteroaryl comprise 5 or 6 chain links and comprise one or more nitrogen heteroatoms;
R 4 RepresentativeThe C1-C4 alkyl;
For alkali or with the additive salt form of acid, and its enantiomer, diastereoisomer, and their mixture.
4. according to claim 1 formula (I) compound is characterised in that
R1 and R2
(1) independently of one another representative:
. perhaps hydrogen atom,
. perhaps C1-C4 alkyl or C3-C8 cycloalkyl, wherein said alkyl randomly replace with one or more groups that are selected from hydroxyl and C1-C4 alkoxyl group,
. the phenyl that perhaps randomly replaces with one or more C1-C4 alkoxyl groups,
. perhaps 5-or 6-the unit heteroaryl, it is selected from thienyl,
(2) or R
1And R
2Form with the carbon atom that carries them:
.C4-C8 cycloalkyl,
For alkali or with the additive salt form of acid, and its enantiomer, diastereoisomer, and their mixture.
5. according to claim 1 formula (I) compound is characterised in that
R
3
Representative:
. the perhaps C1-C4 alkyl of straight or branched or its at least 3 carbon atoms C3-C7 alkyl of carrying out cyclisation, described alkyl randomly is selected from following group and replaces with one or more: the C1-C4 alkoxyl group, the C3-C7 alkyl that wherein said at least 3 carbon atoms carry out cyclisation is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and methylene radical-cyclopropyl
. perhaps-(CH
2)
n-heterocyclic group, n=0 or 1 wherein, wherein this heterocyclic group is selected from THP trtrahydropyranyl, tetrahydrofuran base and pyrrolidyl,
. or-(CH
2)
n-heteroaryl, n=1 wherein, wherein this heteroaryl comprises 5 or 6 chain links and comprises one or more nitrogen heteroatoms and be pyridyl;
For alkali or with the additive salt form of acid, and its enantiomer, diastereoisomer, and their mixture.
6. according to claim 1 formula (I) compound is characterised in that
R 4 Represent methylidene;
For alkali or with the additive salt form of acid, and its enantiomer, diastereoisomer, and their mixture.
7. according to claim 1 formula (I) compound is characterised in that it is selected from:
■ 2-amino-1-ethyl-7-(3-hydroxy-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[(1-hydroxycyclopent base) ethynyl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-cyclopropyl-3-hydroxyl third-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ 2-amino-1-ethyl-7-[(1-hydroxyl cyclobutyl) ethynyl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-ethyl-7-[3-hydroxyl-3-(3-p-methoxy-phenyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-1-(3-methoxy-propyl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-1-(tetrahydropyran-4-base)-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxy-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(tetrahydrofuran (THF)-2-ylmethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (±)-2-amino-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-1-(pyridine-2-ylmethyl)-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-7-(3,4-dihydroxyl-3-methyl fourth-1-alkynes-1-yl)-1-ethyl-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-ethyl-7-(3-hydroxyl-3-phenyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-cyclohexyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-ethyl-7-(3-hydroxyl-4-methoxyl group-3-methyl fourth-1-alkynes-1-yl)-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (+)-2-amino-1-ethyl-7-[3-hydroxyl-3-(3-thienyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide
■ (-)-2-amino-1-ethyl-7-[3-hydroxyl-3-(3-thienyl) fourth-1-alkynes-1-yl]-N-methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1,8-naphthyridines-3-methane amide.
8. formula (VII) compound
Wherein X is halogen atom and R
3And R
4Such as claim in front in each definition.
9. the preparation method of each formula (I) compound is characterised in that to make formula (VII) compound according to claim 1-7
Wherein X is halogen atom and R
3And R
4Such as claim in front in each definition, with the compound reaction of (VIII)
R wherein
1And R
2Such as claim in front in each definition.
10. medicine, be characterised in that its comprise according to claim 1-7 each formula (I) compound or the additive salt of this compound and pharmaceutically acceptable acid, or enantiomer, diastereoisomer or their mixture of formula (I) compound.
11. pharmaceutical composition, be characterised in that it comprises according to claim 1-7 each formula (I) compound or pharmacologically acceptable salts, or the enantiomer of this compound or diastereoisomer, their mixture, and at least a pharmaceutically useful vehicle.
12. the combined prod of each formula (I) compound and at least a chemotherapeutics according to claim 1-7, described chemotherapeutics is selected from:
● alkylating agent,
● intercalating agent,
● antiseptic-germicide,
● antimitotic agent,
● antimetabolite,
● antiproliferative,
● microbiotic,
● immunomodulator,
● antiphlogistic,
● kinase inhibitor,
● anti-angiogenic agent,
● anti-angiogenic dose,
● female hormone and male hormone.
13. each formula (I) compound is for the preparation of the purposes of medicine according to claim 1-7, this medicine is used for the treatment of all diseases that wherein relate to VEGFR-3.
14. each formula (I) compound is for the preparation of the purposes of medicine according to claim 1-7, this medicine is used for the treatment of and/or preventing cancer and its transfer.
15. formula according to claim 14 (I) compound is for the preparation of the purposes of medicine, this medicine is used for the treatment of and/or prevents glioblastoma, multiple myeloma, myelodysplastic syndrome, mammary cancer, colorectal carcinoma, carcinoma of the pancreas, prostate cancer, kidney, incidence cancer, liver cancer, ovarian cancer, respiratory tract and chest organ cancer, or the tumour of other VEGF expression R-3 or relate to that blood vessel occurs or the tumour of lymphatic vessel generative process.
16. formula according to claim 14 (I) compound is for the preparation of the purposes of medicine, this medicine is used for the treatment of and/or prevents noumenal tumour.
17. formula according to claim 14 (I) compound is for the preparation of the purposes of medicine, this medicine is used for the treatment of and/or prevents Kaposis sarcoma, skin heart sarcoma, lymphoma, melanoma and lung cancer.
18. purposes according to claim 17, wherein said lung cancer are non-small cell carcinoma.
19. each formula (I) compound is for the preparation of the purposes of medicine according to claim 1-7, the non-tumor proliferation disease that this medicine is used for the treatment of and/or prevention is relevant with VEGFR-3 and pathology blood vessel occur.
20. formula according to claim 19 (I) compound is for the preparation of the purposes of medicine, this medicine is used for the treatment of and/or prevents to be selected from following disease: joint disease, restenosis, psoriasis, vascular tumor, lymphangioma, glaucoma, glomerulonephritis, diabetic nephropathy, nephrosclerosis, thrombotic microangiopathy syndrome, liver cirrhosis, atherosclerosis, organ-graft refection, relate to that blood vessel occurs or the ophthalmic of lymphatic vessel generative process.
21. each formula (I) compound is for the preparation of the purposes of medicine according to claim 1-7, this medicine is used for the treatment of and/or prevents because the chronic or non-chronic inflammation that infected by microbes and autoimmune disease produce.
22. each formula (I) compound is for the preparation of the purposes of medicine according to claim 1-7, this medicine is used for the treatment of and/or prevents because the chronic or non-chronic inflammation that polyarthritis destruens produces.
23. each formula (I) compound is for the preparation of the purposes of medicine according to claim 1-7, this medicine is used for the treatment of and/or prevents LAM.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0704192 | 2007-06-13 | ||
| FR0704192A FR2917412B1 (en) | 2007-06-13 | 2007-06-13 | 7-ALKYNYL, 1,8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| PCT/FR2008/000793 WO2009007535A2 (en) | 2007-06-13 | 2008-06-11 | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101679427A CN101679427A (en) | 2010-03-24 |
| CN101679427B true CN101679427B (en) | 2013-02-20 |
Family
ID=38870275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880020027XA Active CN101679427B (en) | 2007-06-13 | 2008-06-11 | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics |
Country Status (45)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2917413B1 (en) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | 7-ALKYNYL-1,8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| FR2933700B1 (en) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| FR2952934B1 (en) | 2009-11-23 | 2012-06-22 | Sanofi Aventis | PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| FR2954943B1 (en) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | ARYLSULFONAMIDE PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
| FR2955109B1 (en) * | 2010-01-08 | 2012-09-07 | Sanofi Aventis | 5-OXO-5,8-DIHYDRO-PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| FR2965263A1 (en) | 2010-09-24 | 2012-03-30 | Sanofi Aventis | THIENOPYRIDINE NICOTINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| JP5748210B2 (en) * | 2011-05-26 | 2015-07-15 | 日本化薬株式会社 | Method for producing heterocyclic compound |
| HUE035712T2 (en) | 2012-07-17 | 2018-05-28 | Sanofi Sa | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma |
| CN108558869B (en) * | 2018-05-10 | 2019-04-09 | 西安培华学院 | For treating the compound and its preparation of liver cancer |
| CN110981869A (en) * | 2019-12-10 | 2020-04-10 | 天津科技大学 | Synthesis method of 1, 8-bis-azachromone and application of 1, 8-bis-azachromone in antidiabetic drugs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0978516A1 (en) * | 1998-01-29 | 2000-02-09 | Suntory Limited | 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9800921A (en) * | 1995-08-02 | 1998-05-31 | Chirotech Technology Ltd | Quinolones and their therapeutic use. |
| CA2447765C (en) * | 2001-05-24 | 2011-01-25 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| JP2008501628A (en) | 2004-06-02 | 2008-01-24 | 武田薬品工業株式会社 | Indole derivatives and cancer therapeutic applications |
| FR2917413B1 (en) * | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | 7-ALKYNYL-1,8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
-
2007
- 2007-06-13 FR FR0704192A patent/FR2917412B1/en not_active Expired - Fee Related
-
2008
- 2008-05-27 PA PA20088781701A patent/PA8781701A1/en unknown
- 2008-06-11 TW TW097121818A patent/TWI405762B/en not_active IP Right Cessation
- 2008-06-11 SI SI200830273T patent/SI2158201T1/en unknown
- 2008-06-11 CN CN200880020027XA patent/CN101679427B/en active Active
- 2008-06-11 EP EP08826268A patent/EP2158201B1/en active Active
- 2008-06-11 AP AP2010005099A patent/AP2590A/en active
- 2008-06-11 CA CA2690337A patent/CA2690337C/en active Active
- 2008-06-11 PE PE2008000997A patent/PE20090307A1/en not_active Application Discontinuation
- 2008-06-11 ME MEP-2009-346A patent/ME00961B/en unknown
- 2008-06-11 UA UAA201000231A patent/UA96994C2/en unknown
- 2008-06-11 EA EA201070009A patent/EA016939B1/en not_active IP Right Cessation
- 2008-06-11 DE DE602008006188T patent/DE602008006188D1/en active Active
- 2008-06-11 PT PT08826268T patent/PT2158201E/en unknown
- 2008-06-11 AU AU2008274099A patent/AU2008274099B2/en active Active
- 2008-06-11 NZ NZ581839A patent/NZ581839A/en not_active IP Right Cessation
- 2008-06-11 BR BRPI0814035-9A patent/BRPI0814035B1/en active IP Right Grant
- 2008-06-11 DK DK08826268.8T patent/DK2158201T3/en active
- 2008-06-11 AR ARP080102477A patent/AR066954A1/en unknown
- 2008-06-11 MY MYPI20095271A patent/MY157754A/en unknown
- 2008-06-11 MX MX2009013515A patent/MX2009013515A/en active IP Right Grant
- 2008-06-11 ES ES08826268T patent/ES2365073T3/en active Active
- 2008-06-11 JP JP2010511680A patent/JP5343072B2/en active Active
- 2008-06-11 PL PL08826268T patent/PL2158201T3/en unknown
- 2008-06-11 KR KR1020097025888A patent/KR101517636B1/en not_active IP Right Cessation
- 2008-06-11 AT AT08826268T patent/ATE505469T1/en active
- 2008-06-11 WO PCT/FR2008/000793 patent/WO2009007535A2/en active Application Filing
- 2008-06-12 JO JO2008277A patent/JO2682B1/en active
- 2008-06-13 UY UY31152A patent/UY31152A1/en not_active Application Discontinuation
- 2008-06-13 CL CL2008001775A patent/CL2008001775A1/en unknown
-
2009
- 2009-11-18 TN TNP2009000483A patent/TN2009000483A1/en unknown
- 2009-11-25 DO DO2009000264A patent/DOP2009000264A/en unknown
- 2009-12-01 GT GT200900309A patent/GT200900309A/en unknown
- 2009-12-03 SV SV2009003429A patent/SV2009003429A/en not_active Application Discontinuation
- 2009-12-03 NI NI200900211A patent/NI200900211A/en unknown
- 2009-12-04 US US12/631,122 patent/US8470847B2/en active Active
- 2009-12-09 EC EC2009009791A patent/ECSP099791A/en unknown
- 2009-12-09 IL IL202640A patent/IL202640A/en not_active IP Right Cessation
- 2009-12-10 CR CR11157A patent/CR11157A/en unknown
- 2009-12-10 CO CO09141427A patent/CO6150150A2/en unknown
- 2009-12-11 HN HN2009003402A patent/HN2009003402A/en unknown
-
2010
- 2010-01-12 MA MA32508A patent/MA31567B1/en unknown
- 2010-08-26 HK HK10108139.3A patent/HK1141790A1/xx not_active IP Right Cessation
-
2011
- 2011-06-16 CY CY20111100571T patent/CY1111631T1/en unknown
- 2011-07-11 HR HR20110515T patent/HRP20110515T1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0978516A1 (en) * | 1998-01-29 | 2000-02-09 | Suntory Limited | 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity |
Non-Patent Citations (4)
| Title |
|---|
| Pharmaceutical Bulletin》.1972,第20卷(第4期),639-649. * |
| Senkichi Nagasaki et al.,.Studies on the Antibacterial Activity of 1-Substituted 1,4-Dihydro-7-[2-(5-nitro-2-furyl)vinyl]-4-oxo-1,8-naphthyridine Derivatives.《Chemical & Pharmaceutical Bulletin》.1972,第20卷(第4期),639-649. |
| Senkichi Nagasaki et al.,.Studies on the Antibacterial Activity of 1-Substituted 1,4-Dihydro-7-[2-(5-nitro-2-furyl)vinyl]-4-oxo-1,8-naphthyridine Derivatives.《Chemical & * |
| 刘明亮.喹诺酮类抗菌药的结构特征及构效关系.《国外医药(抗生素分册)》.1999,第20卷(第3期),116-120. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101679427B (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics | |
| AU2015335694B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| CN104024252B (en) | Be used for the treatment of the bicyclic heterocycle derivatives of pulmonary hypertension | |
| CN113307811B (en) | Tetrahydropyranyl amino-pyrrolopyrimidinones and methods of use thereof | |
| AU2017376629A1 (en) | Benzimidazole compounds as c-Kit inhibitors | |
| CN101815715B (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics | |
| AU2017295628A1 (en) | Heterocyclic compound used as FGFR inhibitor | |
| TW201731841A (en) | 6-aryl or 6-heteroaryl 4-morpholin-4-yl-pyridine-2-one compounds | |
| KR20170106294A (en) | Six-membered ring benzo deribatibes as dpp-4 inhibitor and use thereof | |
| KR102262275B1 (en) | Chiral heterocyclic compounds having hedgehog pathway antagonist activity, methods and uses thereof | |
| AU2017220984B2 (en) | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | |
| US9713615B2 (en) | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | |
| JP2017521489A (en) | Pyrimidine compounds and methods of use thereof | |
| Liu et al. | Synthesis and anti-hepatitis B virus evaluation of novel ethyl 6-hydroxyquinoline-3-carboxylates in vitro | |
| CN113166109B (en) | Aminopyridine compound and preparation method and application thereof | |
| KR101418078B1 (en) | 2-(Substituted ethynyl)quinoline derivatives as mGluR5 antagonists | |
| TWI750645B (en) | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof | |
| NZ795496A (en) | Aminothiazole compounds as c-Kit inhibitors | |
| NZ795495A (en) | Aminothiazole compounds as c-Kit inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1141790 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1141790 Country of ref document: HK |